EUVIMEDEUVIMED entdecken
Open Access

Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy

Sha Zhou, Yuting Wang, Rui Zhang, Weian Zeng, Shiliang Liu, Songran Liu, Mengzhong Liu, Hong Yang, Mian Xi

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2022.50965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Sha Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzho…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Sialic acid–binding immunoglobulin-like lectin 15 (Siglec-15) is a novel immune checkpoint molecule that is highly homologous to programmed cell death ligand 1 (PD-L1), but information remains limited about its role in esophageal squamous cell carcinoma (ESCC).

Objective

To explore the expression pattern and association of Siglec-15 with outcomes among patients with ESCC who received neoadjuvant chemoradiotherapy (CRT). Design, Setting, and Participants This retrospective cohort study was conducted at an academic institution in China. Participants included patients with ESCC who underwent neoadjuvant CRT and esophagectomy between June 2002 and December 2018. Multiplexed immunofluorescence staining was used to evaluate the expression of Siglec-15 and PD-L1 in tumor cells (TCs) or tumor-associated macrophages based on pre-CRT biopsies. Different immune phenotypes have been proposed and further validated in an independent cohort. Data analysis was conducted from January to May 2021. Exposures Siglec-15 or PD-L1 positivity vs negativity. Main Outcomes and Measures Pathologic complete response (pCR), overall survival (OS), and recurrence-free survival (RFS).

Results

Of 130 participants (median [range] age, 56 [42-73] years; 108 [83.1%] male participants) in the primary cohort, 58 patients (44.6%) achieved a pCR after neoadjuvant CRT. Siglec-15 and PD-L1 were detected in both TCs and macrophages. The percentage of Siglec-15–positive macrophages was notably higher than that of Siglec-15–positive TCs (median [IQR]: 34.4% [12.7%-64.3%] vs 4.8% [0.7%-25.6%]; P < .001). TC–Siglec-15 expression was significantly and positively associated with macrophage–Siglec-15 expression ( r = 0.78; P < .001). Siglec-15 positivity was significantly associated with a higher rate of pCR (37 of 70 [52.9%] vs 21 of 60 [35.0%]; P = .04), more favorable OS (hazard ratio [HR], 0.46; 95% CI, 0.25-0.85; P = .01), and RFS (HR, 0.48; 95% CI, 0.26–0.88; P = .02). However, PD-L1 positivity in TCs was negatively associated with survival. Stratification analysis further revealed that patients with combined Siglec-15 positivity and PD-L1 negativity had better survival than those with other phenotypes. Major findings were reproducible in a validation cohort with 55 patients. Conclusions and Relevance In this cohort study of patients with ESCC receiving neoadjuvant CRT, Siglec-15 positivity was associated with a better pathological response and more favorable survival. Siglec-15 could serve as a novel biomarker to identify potential candidates that may benefit from immunotherapy combined with CRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleHumansMaleB7-H1 AntigenCohort StudiesImmunoglobulinsN-Acetylneuraminic AcidNeoadjuvant TherapyPhenotypePrognosisRetrospective StudiesSialic Acid Binding Immunoglobulin-like LectinsMembrane Proteins

Substanzen

B7-H1 AntigenImmunoglobulinsN-Acetylneuraminic AcidSialic Acid Binding Immunoglobulin-like LectinsSIGLEC15 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.
  • Department of Anesthesiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Radiotherapy, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
  • School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming, China.
  • Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China.

Zitieren

APA

Zhou, S., Wang, Y., Zhang, R., Zeng, W., Liu, S., Liu, S., Liu, M., Yang, H., & Xi, M. (2023). Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2022.50965

Vancouver

Zhou S, Wang Y, Zhang R, Zeng W, Liu S, Liu S, et al. Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2022.50965

BibTeX
@article{Zhou2023,
  author = {Zhou, Sha and Wang, Yuting and Zhang, Rui and Zeng, Weian and Liu, Shiliang and Liu, Songran and Liu, Mengzhong and Yang, Hong and Xi, Mian},
  title = {Association of Sialic Acid–Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2022.50965}
}
Kostenlos starten →